Yusheng Jie1, Xiangyong Li1, Guoli Lin1, Yuankai Wu1, Xinhua Li1, Zhiliang Gao1, Yutian Chong2. 1. Department of Infectious Diseases, The Third Affiliated Hospital, Sun Yat-sen University, Tianhe Road No. 600, Guangzhou, 510630, China. 2. Department of Infectious Diseases, The Third Affiliated Hospital, Sun Yat-sen University, Tianhe Road No. 600, Guangzhou, 510630, China. chongyutian_1980@163.com.
Abstract
PURPOSE: To analyze the spectrum of diseases in patients with chronic hepatitis B virus (HBV) infection and their association with patient clinicopathologic characteristics and the effect of antiviral therapy on the spectrum of diseases in the study cohort. METHODS: We retrospectively reviewed the clinicopathologic and virologic records of patients with chronic HBV infection hospitalized at our institution during 2011. Demographic data, hepatitis B e antigen (HBeAg) status and HBV DNA (log10 IU/ml) were obtained. RESULTS: A total of 1,619 patients were included; 272 (17.2 %) patients received antiviral therapy for a mean duration of 24.5 ± 18.3 months, and 71.0 % (198/279) patients were compliant with their antiviral therapy. HBeAg-positive patients had a markedly higher rate of moderate and severe CHB than HBeAg-negative patients (p < 0.001) but a significantly lower rate of liver cirrhosis (p < 0.001). The rate of severe and fulminant CHB was significantly lower in patients receiving antiviral therapy than in those not receiving antiviral therapy. CONCLUSIONS: Patients receiving antiviral therapy exhibit a different spectrum of diseases from patients not receiving such therapy.
PURPOSE: To analyze the spectrum of diseases in patients with chronic hepatitis B virus (HBV) infection and their association with patient clinicopathologic characteristics and the effect of antiviral therapy on the spectrum of diseases in the study cohort. METHODS: We retrospectively reviewed the clinicopathologic and virologic records of patients with chronic HBV infection hospitalized at our institution during 2011. Demographic data, hepatitis B e antigen (HBeAg) status and HBV DNA (log10 IU/ml) were obtained. RESULTS: A total of 1,619 patients were included; 272 (17.2 %) patients received antiviral therapy for a mean duration of 24.5 ± 18.3 months, and 71.0 % (198/279) patients were compliant with their antiviral therapy. HBeAg-positive patients had a markedly higher rate of moderate and severe CHB than HBeAg-negative patients (p < 0.001) but a significantly lower rate of liver cirrhosis (p < 0.001). The rate of severe and fulminant CHB was significantly lower in patients receiving antiviral therapy than in those not receiving antiviral therapy. CONCLUSIONS:Patients receiving antiviral therapy exhibit a different spectrum of diseases from patients not receiving such therapy.
Authors: Yun-Fan Liaw; Joseph J Y Sung; Wan Cheng Chow; Geoffrey Farrell; Cha-Ze Lee; Hon Yuen; Tawesak Tanwandee; Qi-Min Tao; Kelly Shue; Oliver N Keene; Jonathan S Dixon; D Fraser Gray; Jan Sabbat Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Jules L Dienstag; Robert D Goldin; E Jenny Heathcote; H W L Hann; Mary Woessner; Sally L Stephenson; Stephen Gardner; D Fraser Gray; Eugene R Schiff Journal: Gastroenterology Date: 2003-01 Impact factor: 22.682